Marginal zone lymphoma
Therapeutic area
Hematology
Rare disease
Yes
- Definition
- A usually indolent mature B-cell lymphoma, arising from the marginal zone of lymphoid tissues. It is characterized by the presence of small to medium sized atypical lymphocytes. It comprises three entities, according to the anatomic sites involved: extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue, which affects extranodal sites (most often stomach, lung, skin, and ocular adnexa); nodal marginal zone B-cell lymphoma, which affects lymph nodes without evidence of extranodal disease; and splenic marginal zone B-cell lymphoma, which affects the spleen and splenic hilar lymph nodes, bone marrow, and often the peripheral blood.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Marginal zone lymphoma
- Therapeutic area
- Hematology
- marginal zone lymphoma
- MZBCL
- MZL
- lymphoma of marginal zone B cell
- marginal zone B cell lymphoma
- marginal zone B-cell lymphoma
- marginal zone lymphoma
- Severity
- Severe
- Hematology
- Immunology
- Oncology
- MONDO ID
- MONDO:0017604
- Parent condition
- MONDO:0017594
Related records
Broader conditions (23)
- B-cell neoplasm
- B-cell non-Hodgkin lymphoma
- Cancer or benign tumor
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Hematologic disorder
- Hematopoietic and lymphoid cell neoplasm
- Hematopoietic and lymphoid system neoplasm
- Human disease
- Immune system disorder
- Indolent B-cell non-Hodgkin lymphoma
- Leukocyte disorder
- Lymphatic system disorder
- Lymphoid hemopathy
- Lymphoid neoplasm
- Lymphoid system disorder
- Lymphoma
- Neoplasm
- Neoplastic disease or syndrome
Narrower conditions (9)
- Breast mucosa-associated lymphoid tissue lymphoma
- Gastric mucosa-associated lymphoid tissue lymphoma
- MALT lymphoma
- Nodal marginal zone B-cell lymphoma
- Small intestinal mucosa-associated lymphoid tissue lymphoma
- Splenic diffuse red pulp small B-cell lymphoma
- Splenic marginal zone lymphoma
- Thyroid gland mucosa-associated lymphoid tissue lymphoma
- Tonsillar lymphoma
Trials (351)
- (CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)
- [68Ga]Ga-PentixaFor-PET Imaging for Staging of Marginal Zone Lymphoma
- 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation
- 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas
- 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer
- 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma
- 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers
- 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
- 506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma
- 64Cu-LLP2A for Imaging Hematologic Malignancies
- A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies
- A Cohort Study in Newly Diagnosed MZL
- A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
- A Phase 1 Study of ADI-001 in B Cell Malignancies
- A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
- A Phase I/II Study of Intratumoral Injection of SD-101
- A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
- A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies
- A Phase II Study of Doxycycline in Relapsed NHL
Approved drugs (1)
- Umbralisib tosylate
Drugs in development (23)
- Acalabrutinib Phase 2
- Bendamustine Phase 3
- Copanlisib Phase 2
- Cyclophosphamide Phase 3
- Dextrose Phase 3
- Doxorubicin Phase 3
- Everolimus Phase 2
- Ianalumab Phase 1
- Ibrutinib Phase 3
- Irinotecan hydrochloride Phase 1
- Lenalidomide Phase 3
- Mosunetuzumab Phase 2
- Obinutuzumab Phase 2
- Orelabrutinib Phase 3
- Pembrolizumab Phase 2
- Pirtobrutinib Phase 2
- Polatuzumab vedotin Phase 2
- Prednisone Phase 3
- Rituximab Phase 3
- Tafasitamab Phase 2
Other linked drugs (1)
- Umbralisib